Circius Pharma ApS Financials, key figures and credit report
Gross profit 2 858.3 kDKK FY 2025 +4% vs 2024
EBIT 57.6 kDKK FY 2025 +16.5% vs 2024
Net debt 55.1 kDKK FY 2025 -96% vs 2024
Quick ratio 3.9 FY 2025 -1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | - 872.07 | 2 765.69 | 2 770.37 | 2 749.40 | 2 858.28 |
| Employee benefit expenses | - 230.61 | -2 085.74 | -2 017.49 | -2 006.13 | -2 106.85 |
| Other operating expenses | -0.80 | -1.11 | |||
| Total depreciation | - 231.28 | - 693.85 | -2 936.30 | - 693.85 | - 693.85 |
| EBIT | -1 334.77 | -15.00 | -2 183.42 | 49.42 | 57.58 |
| Other financial income | 54.17 | 1.70 | 7.03 | 1.50 | |
| Other financial expenses | -8.04 | -55.08 | -60.73 | -56.45 | -59.08 |
| Pre-tax profit | -1 342.81 | -15.91 | -2 242.45 | ||
| Net earnings | -1 342.81 | -15.91 | -2 242.45 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Goodwill | 6 707.20 | 6 013.35 | 3 077.05 | 2 383.20 | 1 689.36 |
| Intangible assets total | 6 707.20 | 6 013.35 | 3 077.05 | 2 383.20 | 1 689.36 |
| Tangible assets total | |||||
| Investments total | 156.00 | 42.00 | 43.26 | 43.26 | 43.26 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 2 456.15 | 2 878.74 | 2 176.47 | 1 727.84 | 1 498.64 |
| Current amounts owed by group member comp. | 661.55 | 672.29 | 1 526.74 | 1 174.05 | |
| Prepayments and accrued income | 208.35 | 14.09 | 24.67 | 25.15 | 26.64 |
| Current other receivables | 0.11 | 6.00 | 2.16 | 1.91 | 2.24 |
| Short term receivables total | 2 664.61 | 3 560.39 | 2 875.58 | 3 281.64 | 2 701.57 |
| Cash and bank deposits | 130.47 | 181.03 | 663.12 | 1 017.64 | 982.84 |
| Cash and cash equivalents | 130.47 | 181.03 | 663.12 | 1 017.64 | 982.84 |
| Balance sheet total (assets) | 9 658.28 | 9 796.77 | 6 659.01 | 6 725.75 | 5 417.02 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Retained earnings | 6 938.48 | 5 595.68 | 5 579.77 | 3 337.32 | 3 337.32 |
| Profit of the financial year | -1 342.81 | -15.91 | -2 242.45 | ||
| Shareholders equity total | 5 695.68 | 5 679.77 | 3 437.32 | 3 437.32 | 3 437.32 |
| Non-current owed to group member | 1 709.00 | 3 183.99 | 1 905.66 | 2 405.66 | 1 030.08 |
| Non-current liabilities total | 1 709.00 | 3 183.99 | 1 905.66 | 2 405.66 | 1 030.08 |
| Current loans from credit institutions | 7.88 | ||||
| Current trade creditors | 988.27 | 278.65 | 530.00 | 101.10 | 302.57 |
| Current owed to group member | 909.48 | ||||
| Other non-interest bearing current liabilities | 104.01 | 654.36 | 786.03 | 781.67 | 639.18 |
| Accruals and deferred income | 251.85 | ||||
| Current liabilities total | 2 253.61 | 933.01 | 1 316.03 | 882.77 | 949.63 |
| Balance sheet total (liabilities) | 9 658.28 | 9 796.77 | 6 659.01 | 6 725.75 | 5 417.02 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated